Lipid Profile,Low-Density Lipoprotein Oxidation and Ceruloplasmin in the Progeny of Families with a Positive History of Cardiovascular Diseases and/or Hyperlipidemia
Restricted accessResearch articleFirst published online August, 2009
Lipid Profile,Low-Density Lipoprotein Oxidation and Ceruloplasmin in the Progeny of Families with a Positive History of Cardiovascular Diseases and/or Hyperlipidemia
Fifty-eight healthy progeny (mean age ± SD 13.9 ± 7.9 years) of 39 families with a positive history for Cardiovascular Diseases ([CVD] n = 44) or hyperlipidemia (n = 14) were included in the study and were compared with 30 age-matched control participants, with a negative family history, to evaluate lipid profile, ceruloplasmin (Cp), and lipid peroxidation product (malondialdehyde [MDA]) levels, as well as in vitro copper-induced Low-density lipoprotein (LDL) oxidizability. Mean serum levels of total cholesterol, LDL cholesterol (LDL-C), apolipoprotein B-100, and MDA of the participants were significantly higher than those of the controls. Lag time, an LDL resistance oxidation marker, was lower in the study group and negatively correlated with LDL-C (r = -.437, P < .05) and Cp (r = -.272, P < .05) serum levels. In conclusion, progeny with a positive family history for CVD or hyperlipidemia have an atherogenic lipid profile and increased LDL susceptibility to oxidation. High Cp levels seem to be related to lower resistance of LDL to oxidation.
The Lipid Research Clinics Coronary Primary Prevention Trial results.II: The relationship of reduction in incidence of coronary heart disease to cholesterol lowering.J Am Med Assoc.1984; 251(3): 365–374.
2.
Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).J Am Med Assoc.1993; 269(23): 3015–3023.
3.
McGillH.C.Jr., McMahanC.A., ZieskeA.W. for the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Effect of nonlipid risk factors on atherosclerosis in youth with favorable lipoprotein profile.Circulation.2001; 103: 1546–1550.
4.
Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking.A preliminary report from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group.J Am Med Assoc.1990; 264(23): 318–324.
5.
WeinsteinD.B., CarewT.E., SteinbergD.Uptake and degradation of low density lipoprotein by swine arterial smooth muscle cells with inhibition of cholesterol biosynthesis.Biochem Biophys Acta.1976; 424(3): 404–421.
6.
GoldsteinJ.L., HoY.K., BasuS.K., BrownM.S.Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition.Proc Natl Acad Sci USA.1979; 76(1): 333–337.
7.
EsterbauerH., GebickiJ., PuhlH., JürgensG.The role of lipid peroxidation and antioxidants in oxidative modification of LDL.Free Radic Biol Med.1992; 13(4): 341–390.
8.
SteinbrecherU.P., ParthasarathyS., LeakeD.S., WitztumJ.L., SteinbergD.Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids.Proc Natl Acad Sci USA.1984; 81(12): 3883–3887.
9.
SteinbergD., ParthasarathyS., CarewT.E., KhooJ.C., WitztumJ.L.Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.N Engl J Med.1989; 320(14): 915–924.
10.
PitasR.E.Expression of the acetyl low density lipoprotein receptor by rabbit fibroblasts and smooth muscle cells. Up-regulation by phorbol esters.J Biol Chem.1990; 265(21): 12722–27.
Osborn-BarnesH.T., AkohC.C.Effects of a-tocopherol, beta-carotene, and soy isoflavones on lipid oxidation of structured lipid-based emulsions.J Agric Food Chem.2003; 51(23): 6856–6860.
13.
SiemsW., WiswedelI., SalernoC.Beta-carotene breakdown products may impair mitochondrial functions-potential side effects of high dose beta-carotene supplementation.J Nutr Biochem.2005; 16(7): 385–397.
14.
GalassettiP., PontelloA.Dietary effects on oxidation of low-density lipoprotein and atherogenesis.Curr Atheroscler Rep.2006; 8(6): 523–529.
15.
GimenoE., de la Torre-CarbotK., Lamuela-RaventosR.M.Changes in the phenolic content of low density lipoprotein after olive oil consumption in men. A randomized crossover controlled trial.Br J Nutr.2007; 98(6): 1243–1250.
SaenkoE.L., YaropolovAl, HarrisE.D.Biological functions of ceruloplasmin expressed through copper-binding sites and a cellular receptor.J Trace Elem Exp Med.1994; 7: 69–88.
18.
KlebanoffS.J.Bactericidal effect of Fe21, ceruloplasmin, and phosphate.Arch Biochem Biophys.1992; 295(2): 302–308.
EhrenwaldE., ChisolmG.M., FoxP.L.Intact human ceruloplasmin oxidatively modifies low density lipoprotein.J Clin Invest.1994; 93(4): 1493–1501.
21.
SalonenJ.T., SalonenR., KorpelaH., SuntioinenS., TuomilehtoJ.Serum copper and the risk of acute myocardial infarction: a prospective population study in men in Eastern Finland.Am J Epidemiol.1991; 134(3): 268–276.
22.
Klipstein-GrobuschK., GrobbeeD.E., KosterJ.F.Serum caeruloplasmin as a coronary risk factor in the elderly: the Rotterdam Study.Br J Nutr.1999; 81(2): 139–144.
23.
National Cholesterol Education Program Report of the Expert panel on Blood Cholesterol levels in children and adolescents.Pediatrics.1992; 89(3 pt 2): 525–584.
LowryO.H., RosebroughN.J., FarrA.L., RandallR.J.Protein measurement with the Folin phenol reagent.J Biol Chem.1951; 193(1): 265–275.
26.
BotsoglouN.A., FletourisD.J., PapgeorgiouG.E., VassilopoulosV.N., MantisA.J., TrakatellisA.G.Rapid, sensitive and specific thiobarbituric acid method for measuring lipid peroxidation in animal tissue, food and feedstuff samples.J Agric Food Chem.1994; 42(9): 1931–1937.
27.
CastelliW.P.Epidemiology of triglyceride: a review from Framingham.Am J Cardiol.1992; 70: 3–9.
28.
AssmanG., SchulteH.Role of TG in coronary artery disease: lessons from the prospective cardiovascular Munster Study.Am J Cardiol.1992; 70: 10–13.
29.
FreedmanD.S., SrinivasanS.R., CresantaJ.L., WebberL.S., BerensonG.S.Cardiovascular risk factors from birth to 7 years of age: the Bogalusa Heart Study. Serum lipids and lipoproteins.Pediatrics.1987; 80(5 pt 2): 789–796.
30.
KostnerG.M., CzinnerA., PfeifferK.H., Bihari-VargaM.Lipoprotein (a) concentrations as risk indicators for atherosclerosis.Arch Dis Child.1991; 66(9): 1054–1056.
31.
MakedouA., KourtiM., MakedouK., LazandouS., VarlamisG.Lipid profile of children with family history of coronary heart disease or hyperlipidemia: 9-year experience of the Preventive Cardiovascular outpatient clinic.Angiology.2005; 56(4): 391–395.
32.
HickmanT.B., BriefelR.R., CarrollM.D., RifkindB.M.Distributions and trends of serum lipid levels among United States Children and adolescents Ages 4–19 years: data from the third National Health and Nutrition Examination Survey.Prev Med.1998; 27(6): 879–890.
33.
DavisP.H., DawsonJ.D., RileyW.A., LauerR.M.Carotid intimalmedial thickness is related to cardiovascular risk factors measured from childhood through middle age: the Muscatine Study.Circulation.2001; 104(23): 2815–2819.
34.
BistritzerT., RosenzweigL., BarrJ.Lipid profile with paternal history of coronary heart disease before age 40.Arch Dis Child.1995; 73(1): 62–65.
35.
TerresW., TatsisE., PfalzerB., BeilF.U., BeisiegelU., HammC.W.Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein (a).Circulation.1995; 91(4): 948–950.
MaherV.M., BrownB.G., MarcovinaS.M., HillgerL.A., ZhaoX.Q., AlbersJ.J.Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein (a).JAMA.1995; 274(22): 1771–1774.
38.
US Preventive Services Task Force: Screening and treatment for lipid disorders in children and adolescents: systematic evidence review for the US Preventive Services Task Force.Pediatrics.2007; 120(1): e215–219.
39.
KaveyR.E., DanielsS.R., LauerR.M., AtkinsD.L., HaymanL.L., TaubertK.. American Heart Association. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood.Circulation.2003; 107(11): 1562–1566.
40.
ParthasarathyS., SantanamN., RamachandranS., MeilhacO.Oxidants and antioxidants in the atherogenesis: an appraisal.J Lipid Res.1999; 40(12): 2143–2147.
41.
RegnstromJ., NilssonJ., TornvallP., LandouC., HamstenA.Susceptibility of low density lipoprotein to oxidation and atherosclerosis.Lancet.1992; 339(8803): 883–887.
42.
MakedouA., MakedouK., PapandreouD.Dietary intervention in children with familial hypercholesterolemia.Clin Nutr.2005; 24: 4, Suppl: LB012.
43.
EnbergsA., DorszewskiA., LuftM.Failure to confirm ferritin and caeruloplasmin as risk factors for the angiographic extent of coronary arteriosclerosis.Coron Artery Dis.1998; 9(2–3): 119–124.
44.
ReunanenA., KnektP., AaranR.K.Serum ceruloplasmin level and the risk of myocardial infarction and stroke.Am J Epidemiol.1992; 136(9): 1082–1090.
45.
MänttäriM., ManninenV., HuttunenJ.K.Serum ferritin and ceruloplasmin as coronary risk factors.Eur Heart J.1994; 15(12): 1599–1603.
46.
SalonenJ.T., SalonenR., SeppänenK., KantolaM., SuntioinenS., KorpelaH.Interactions of serum copper, selenium, and low density lipoprotein cholesterol in atherogenesis.Br Med J.1991; 302(6779): 756–760.
47.
MezzettiA., GuglielmiM.D., PierdomenicoS.D.Increased systemic oxidative stress after elective endarterectomy: relation to vascular healing and remodeling.Arterioscler Thromb Vasc Biol.1999; 19(11): 2659–2665.
48.
AwadallahS.M., HamadM., JbarahI., SalemN.M., MubarakM.S.Autoantibodies against oxidized LDL correlate with serum concentrations of ceruloplasmin in patients with cardiovascular disease.Clin Chim Acta.2006; 365(1-2): 330–336.
49.
Ghayour-MobarhanM., LambD.J., TaylorA.Effect of statin therapy on serum trace element status in dyslipidaemic subjects.J Trace Elem Med Biol.2005; 19(1): 61–67.
